NOTCH3 and pulmonary arterial hypertension: These results suggest that androgen receptor inhibitors may exert therapeutic effects in PAH by inhibiting the Notch3/Hes5 pathway, thereby increasing apoptosis in pulmonary tissues and alleviating disease progression (Figure 8) (Jurasz et al., 2010).